FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Kesponse		*	2 Inc.	on NI-	on d 7	Cial.	n on Tas 4:	C-	l. a1		5 D	elationshin	of Reportir	ng Person(s) to	Iccuer	
Name and Address of Reporting Person Brandt Peter C.				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]							RNN]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455				3. Date of Earliest Transaction (Month/Day/Year) 04/11/2017									Officer (give	title below)		(specify below)	
(Street) ROCKVILLE, MD 20850				4. If Amendment, Date Original Filed(Month/Day/Year))	_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(Cit	(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							Acquired,	ired, Disposed of, or Beneficially Owned				
(Instr. 3) De		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Da any (Month/Day/		Date, if	ate, if Code (Instr.		(A)	4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5) (A) or		f (D) Own Tran (Inst	(D) Owned Followi Transaction(s) (Instr. 3 and 4)		d O Fo D	wnership of Be irect (D) Ov Indirect (Ir	eneficial wnership	
		separate line for eac					Coo		Am	Cant (D) [Price			(I	nstr. 4)	
			Table II -					in thi	is fo ays spose	rm are n a currer d of, or l	not re ntly va Benefi	equired to alid OMB icially Own	respond control r	unless the	tion containe e form	SEC 14.	7 - (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. 5. Nun Transaction Deriva Code Securit (Instr. 8) Acquir or Disposition of (D)		5. Number Derivative Securities Acquired or Dispos of (D) (Instr. 3,	mber of 6. Date E Expiratio (Month/I posed 3, 4,		Exerc on Da	xercisable and n Date Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Security: Direct (D) or Indirect	Beneficial
				Code	V	(A)	(D)	Date Exercisa		Expiration Date	on	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 0.618	04/11/2017		A		110,000		04/11/2	018	04/11/2	2027	Common Stock	110,000	\$ 0	110,000	D	

Reporting Owners

Demonstra Common Name / Addison	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Brandt Peter C. C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X						

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Peter C. Brandt	04/12/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.